Skip to content ↓

Explore our work

Press

See press releases and statements, or browse media coverage.

Careers

Join our team to create a healthier world.

Office of Global Innovation

The Office of Global Innovation aims to close the gap between innovation and positive impact on people and communities.

Resources

Browse our publications, fact sheets, special reports, video campaigns and other materials.
Publications

Read the study

Publications

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after randomization. Our objective in this follow-up analysis was to assess the durability of efficacy and safety, including mortality, at 132 weeks.

Both of the bedaquiline-containing regimens maintained superiority to the control regimen, without evidence of increased mortality, providing two additional evidence-based treatment options for patients; previous mortality concerns for bedaquiline were not substantiated.

Recent Abstracts